The non-profit Global Health Drug Discovery Institute (GHDDI) on Thursday launched “AI Kongming,” a Chinese-developed artificial intelligence platform for drug discovery.

The platform covers the entire early-stage drug development process, from target structure analysis, AI-driven molecule generation, and drug design, to activity evaluation and druggability optimization. GHDDI said the system integrates the dispersed knowledge of biology, chemistry, and pharmacology into a unified, digital framework, enabling AI-driven reasoning, creation, and evolution.

As an open-access platform, AI Kongming leverages the expertise of top global research institutions and GHDDI’s years of accumulated real-world R&D data, aiming to streamline the critical technology chain of early drug discovery.